Patent · US Active

Crystalline forms of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders

US9593116B2 · kind B2 · utility

0Cited by

2References

8Claims

0Family size

Assignee

Bristol-Myers Squibb Company · US

Inventors

Ashok Vinayak Purandare · Pennington, US
Honghe Wan · Pennington, US

Key dates

Filing date	May 28, 2014
Grant date	Mar 14, 2017
Priority date	—
Expiry date	May 28, 2034

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P37/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Crystalline form, Form T1H1.5-4, of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl -1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide (Compound (I)) is provided. Also provided is a pharmaceutical composition and an oral dosage form comprising Form T1H1.5-4 of Compound (I) as well as a method of using the Form T1H1.5-4 of Compound for the treatment of myeloproliferative disorders, which include polycythaemia vera, thrombocythaemia and primary myelofibrosis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.